Trials / Completed
CompletedNCT03565159
Pneumococcal Vaccination to Accelerate Immune Recovery in Sepsis Survivors
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 214 (actual)
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust · Academic / Other
- Sex
- All
- Age
- 18 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
The VACIRiSS trial is a phase-IV, multi-centre placebo controlled randomised trial of conjugate pneumococcal vaccine in adult sepsis survivors.
Detailed description
The aim of VACIRiSS trial is to evaluate the immunogenicity and heterologous effects of single dose 13-valent conjugate pneumococcal vaccine (PCV-13) in preventing infection related rehospitalisation in sepsis survivors and to collect outcome event data with necessary precision to inform future definitive trial design.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Prevenar 13 | Pneumococcal polysaccharide conjugate vaccine |
| OTHER | Sodium Chloride 0.9% | Placebo |
Timeline
- Start date
- 2018-08-02
- Primary completion
- 2023-08-31
- Completion
- 2023-08-31
- First posted
- 2018-06-21
- Last updated
- 2023-11-24
Locations
12 sites across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT03565159. Inclusion in this directory is not an endorsement.